STOCK TITAN

Merlin appoints Robert H. Smith interim CEO and chairman

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B3

Rhea-AI Filing Summary

Merlin, Inc. (MRLN) appointed Dr. Robert H. Smith interim CEO and chairman effective November 18, 2026, as Matthew George transitioned from CEO, chairman and director to Founder and Advisor. The board is searching for a permanent CEO and will consider internal and external candidates. Smith’s initial term is six months, extendable in successive three-month periods by mutual agreement. His compensation includes a monthly salary of $48,000 and restricted stock unit awards for 500,000 and 1,500,000 shares, subject to vesting terms tied to continued service; unvested portions vest upon a change of control.

George will serve as Founder and Advisor until the first anniversary of the effective date unless earlier terminated under the agreement, receiving $6,250 monthly as a consultant. The agreement provides for a cash payment equal to one and one-half times his current base salary in 18 monthly installments, a target-performance 2026 bonus and 18 months of subsidized health insurance, subject to release and compliance conditions.

Filing Explained

A change in control on or before the third anniversary can add six months of base salary plus the target bonus to George’s severance.

Merlin entered George’s Transition Agreement on November 18, 2026, creating contingent additional compensation obligations and changing when his outstanding awards may vest.

If a change in control occurs on or before the third anniversary, the agreement provides additional cash equal to six months of base salary plus the target annual bonus; if it occurs on or before the first anniversary, it also provides six additional months of subsidized health insurance.

George’s outstanding options and time-based restricted stock units continue vesting while he serves as Founder and Advisor. When his service ends, then-unvested awards vest except in specified cases: a company termination for cause, or his departure before the first anniversary, when only the portion scheduled to vest through that anniversary vests unless his departure follows the company’s material breach. A change in control on or before the first anniversary fully vests then-unvested awards.

Closing stock price $0.88 per share Common Stock closing price on November 19, 2026
Interim CEO initial term 6 months May be extended for successive three-month periods by mutual agreement
Interim CEO monthly salary $48,000 Dr. Robert H. Smith’s compensation as Interim Chief Executive Officer
Interim CEO RSU Award 500,000 shares Award to Dr. Smith; vesting is subject to the stated service terms
Additional RSU Award 1,500,000 shares Award to Dr. Smith; vests in monthly installments subject to continued service and other terms
Minimum Additional RSU Award vesting 1,000,000 shares No fewer than this number vest if the term concludes before the 12-month anniversary for qualifying reasons
Founder and Advisor monthly fee $6,250 Monthly consultant fee for Matthew George, prorated for partial months
Transition cash payment 1.5 times current base salary Matthew George’s payment is to be made in 18 monthly installments
restricted stock unit awards financial
"two restricted stock unit awards"
Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.
Executive Severance Plan financial
"under the Company’s Executive Severance Plan"
Change of Control financial
"if a Change in Control occurs"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
standstill agreement regulatory
"a standstill agreement for three years"
A standstill agreement is a contract in which one party agrees to pause certain actions — such as making new claims, enforcing debt remedies, or pursuing a takeover bid — for a set period so both sides can negotiate or restructure. Think of it as a temporary pause button that reduces immediate pressure and uncertainty; investors care because it can protect value, buy time for a deal or restructuring to be completed, and signal the likelihood and timing of future corporate developments.
Good Reason financial
"constitutes a resignation for “Good Reason”"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is MRLN’s interim CEO?

Dr. Robert H. Smith is MRLN’s interim CEO and chairman, appointed effective November 18, 2026. The board is searching for a permanent CEO and will consider both internal and external candidates.

What compensation will MRLN’s interim CEO receive?

Dr. Smith will receive a monthly salary of $48,000 and two restricted stock unit awards: one for 500,000 shares and another for 1,500,000 shares. If his term concludes before its 12-month anniversary for reasons other than termination for cause or his early resignation, no fewer than 1,000,000 units in the additional award will vest. Unvested portions vest upon a change of control.

What does MRLN’s agreement with Matthew George provide?

George will receive a $6,250 monthly consulting fee while serving as Founder and Advisor, through the first anniversary of the effective date unless earlier terminated under the agreement. The agreement also provides for a cash payment equal to one and one-half times his current base salary in 18 monthly installments, a target-performance 2026 bonus and 18 months of subsidized health insurance, subject to release and compliance conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Filed pursuant to Rule 424(b)(3)
Registration No. 333-295068
PROSPECTUS SUPPLEMENT No. 5
(to Prospectus dated April 21, 2026)
image.jpg
MERLIN, INC.
This prospectus supplement updates, amends and supplements the prospectus dated April 21, 2026 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-295068). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in:
•our Current Report on Form 8-K filed with the SEC on November 19, 2026, which is set forth below.
This prospectus supplement is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including, any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.
Our shares of Common Stock are listed on the Nasdaq Stock Market LLC under the symbol “MRLN”. On November 19, 2026, the closing price of our Common Stock was $0.88 per share.
We are an “emerging growth company” and a “smaller reporting company” as such terms are defined under the federal securities laws and, as such, are subject to certain reduced public company reporting requirements.
Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.
Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is November 19, 2026.




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 18, 2026

MERLIN, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4239298-1797826
(State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
100 Causeway St., Floor 23
Boston, MA 02114
(Address of principal executive offices) (Zip Code)
(857) 201-3979
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act
Title of each classTrading Symbol(s)
Name of each exchange
on which registered
Common stock, par value $0.0001 per shareMRLN
The Nasdaq Stock Market LLC
(Nasdaq Global Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 18, 2026 (the “Effective Date”), Mr. Matthew George transitioned from serving as the Chief Executive Officer of Merlin, Inc. (“Merlin” or the “Company”) and the Chairman and a member of the Board of Directors of the Company (the “Board”) to the role of Founder and Advisor. In connection with the transition, the Board appointed Dr. Robert H. Smith as Interim Chief Executive Officer and Chairman of the Board. The Board is commencing a search for a permanent CEO and will consider both internal and external candidates.
Biographical Information of Dr. Robert H. Smith
Dr. Smith, age 62, has served as a member of the Board since March 16, 2026. In addition, he has held the roles of Principal at Right Hand Side, a consulting group, and Co-Founder at JATO Foundation since January 2024. Dr. Smith also currently serves as a Senior Advisor to the Office of the Secretary of Defense as part of the Business Operators for National Defense (BOND) program. Prior to that, Dr. Smith was the Chief Executive Officer of Blue Origin, a space startup, from September 2017 until January 2024. Dr. Smith also held various leadership roles in the aerospace industry prior to joining Blue Origin, including at Honeywell Aerospace — where he served in various roles from July 2004 to August 2017 including Chief Technology Officer & President of Mechanical Systems & Components, as well as other roles at United Space Alliance and The Aerospace Corporation. Dr. Smith also currently serves as a director of Parsons Corporation (NYSE: PSN), a role he has held since April 2024 and as an independent director Seurat Technologies, an additive manufacturing company. Dr. Smith holds a bachelor’s degree from Texas A&M in Aerospace Engineering, a master’s degree from Brown in Applied Math and Engineering, a master’s degree from the MIT Sloan School of Management and a Ph.D. in Aerospace Engineering from The University of Texas at Austin.
There are no arrangements or understandings between Dr. Smith and any other person pursuant to which Dr. Smith was selected as Interim Chief Executive Officer, other than with directors or officers of the Company acting solely in those capacities. There are no family relationships between Dr. Smith and any director or executive officer of the Company or person nominated or chosen for either role. Dr. Smith has no direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K.
Transition Agreement with Mr. Matthew George
On November 18, 2026, in connection with Mr. George’s transition from Chief Executive Officer and Chairman and member of the Board to the role of Founder and Advisor, the Company entered into a Transition Agreement with Mr. George (the “Transition Agreement”) that sets forth the terms of Mr. George’s Founder and Advisor role and the amounts payable to Mr. George in connection with the conclusion of his employment as Chief Executive Officer. Mr. George will serve as Founder and Advisor until the first anniversary of the Effective Date, unless earlier terminated by Mr. George for any reason or by the Company for cause. As an independent consultant, Mr. George will receive a monthly fee of $6,250 (pro-rated for partial months) and, at the reasonable request of the Company, will assist in the orderly transition of his duties and responsibilities to such other persons as the Company designates and will provide advice to the Board when and as reasonably requested by the Board and agreed to by Mr. George.
Mr. George’s transition from Chief Executive Officer and Chairman and member of the Board constitutes a resignation for “Good Reason” under the Company’s Executive Severance Plan (the “Severance Plan”). The Transition Agreement provides:
•Mr. George will receive (i) a cash payment equal to one and one-half times his current base salary, paid in eighteen monthly installments, (ii) a 2026 annual bonus, based on target performance and paid in a lump sum following the sixtieth (60th) day after the Effective Date, (iii) eighteen months of subsidized health insurance payments, and (iv) if a Change in Control (as defined in the Severance Plan) occurs (A) on or prior to the third anniversary of the Effective Date, an additional cash payment equal to an additional six months of base salary plus one times his target annual bonus, and (B) on or prior to the first anniversary of the Effective Date, the value of an additional six months of subsidized health insurance; and
•Mr. George’s outstanding options and time-based restricted stock unit awards will continue to vest under the terms of the applicable award agreements and equity incentive plans during the time he serves as Founder and Advisor and, (i) upon termination of Mr. George’s service as Founder and Advisor for any reason other than a termination by the Company for cause or a termination by Mr. George prior to the first anniversary of the Effective Date other than as a result of the Company’s material breach of the Transition Agreement, each then unvested option and restricted stock unit award will become vested and, with respect to the options, exercisable, (ii) if Mr. George



terminates his service prior to the first anniversary of the Effective Date other than as a result of the Company’s material breach of the Transition Agreement, the portion of each award that would have vested through such first anniversary will become vested and, with respect to options, exercisable, or (iii) if a Change of Control occurs on or prior to the first anniversary of the Effective Date, Mr. George’s then-outstanding and unvested equity awards will vest in full.
The Transition Agreement includes non-compete, non-solicit of employees and non-interference with business restrictions, in each case, for the duration of Mr. George’s service as Founder and Advisor, and a standstill agreement for three years following the Effective Date. Mr. George’s service as Founder and Advisor and the above payments and benefits provided to Mr. George pursuant to the Transition Agreement are conditioned on his execution and nonrevocation of a release of claims in favor of the Company and such payments and benefits are also conditioned on his compliance with the terms of the Transition Agreement.
The foregoing summary is qualified in its entirety by reference to the Transition Agreement, which is attached as Exhibit 10.1 to this current report on Form 8-K and which is incorporated by reference into this Item 5.02 and will be filed as an exhibit to the Company’s Form 10-K for the fiscal year ending December 31, 2026.
Offer Letter for Dr. Robert H. Smith
On November 18, 2026, the Company and Dr. Smith entered into a letter agreement (the “Offer Letter”) establishing Dr. Smith’s compensation as Interim Chief Executive Officer of the Company. Dr. Smith’s service as Interim Chief Executive Officer will continue for six months, subject to extension for successive three-month periods on mutual agreement, and will conclude on the first to occur of (a) the date a permanent successor Chief Executive Officer is appointed by the Board, (b) the conclusion of the initial term or a successive term without mutual agreement to continue, or (c) resignation or termination for any reason.
Under the Offer Letter, Dr. Smith’s compensation will consist of a monthly salary of $48,000, prorated for partial months. As additional compensation, Dr. Smith will receive two restricted stock unit awards: (i) an award for 500,000 shares (the “Interim CEO RSU Award”), which will vest on the earlier of the six-month anniversary of the Effective Date or the date Dr. Smith’s service as Interim Chief Executive Officer concludes, so long as such conclusion is not the result of a termination by the Company for cause or an early resignation by Dr. Smith, and (ii) an award for 1,500,000 shares (the “Additional RSU Award”) which will vest in twelve monthly installments, so long as Dr. Smith continues to serve as Interim Chief Executive Officer; provided that, in the event the term concludes prior to the 12-month anniversary of the Effective Date for any reason other than a termination by the Company for cause or early resignation by Dr. Smith, no fewer than 1,000,000 of the restricted stock units subject to the Additional RSU Award will vest. Any unvested portions of the Interim CEO RSU Award and the Additional RSU Award will vest upon a change of control of the Company (as defined in Merlin, Inc.’s 2026 Incentive Award Plan (the “LTIP”)). The Interim CEO RSU Award and the Additional RSU Award will be granted under and subject to the terms and conditions of the LTIP.
During his term as Interim Chief Executive Officer, Dr. Smith will be eligible for benefits consistent with those of senior management and reimbursement of reasonable business expenses under Company policies, including temporary housing near the Company’s headquarters. Dr. Smith will not be eligible to participate in the Severance Plan or any similar Company plan or policy. After his service as Interim Chief Executive Officer ends, he will be compensated under the applicable non-employee director compensation program for so long as he continues to serve as a director.
The foregoing summary is qualified in its entirety by reference to the Offer Letter, which is attached as Exhibit 10.2 to this current report on Form 8-K and which is incorporated by reference into this Item 5.02, will be filed as an exhibit to the Company’s Form 10-K for the fiscal year ending December 31, 2026.
Item 8.01. Other Events.
On November 19, 2026, the Company issued a press release announcing an executive leadership change, a copy of which is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.



Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description
10.1
Transition Agreement, dated as of November 18, 2026, between Merlin, Inc. and Matthew George.
10.2
Offer Letter, dated as of November 18, 2026, between Merlin, Inc. and Robert H. Smith.
99.1
Press Release of Merlin, Inc., dated November 19, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 19, 2026MERLIN, INC.
By:/s/ Leslie Ravestein
Name: Leslie Ravestein
Title: Chief Legal Officer and Secretary

Keep reading